SG10201811017QA - Novel antibody frameworks - Google Patents
Novel antibody frameworksInfo
- Publication number
- SG10201811017QA SG10201811017QA SG10201811017QA SG10201811017QA SG10201811017QA SG 10201811017Q A SG10201811017Q A SG 10201811017QA SG 10201811017Q A SG10201811017Q A SG 10201811017QA SG 10201811017Q A SG10201811017Q A SG 10201811017QA SG 10201811017Q A SG10201811017Q A SG 10201811017QA
- Authority
- SG
- Singapore
- Prior art keywords
- novel antibody
- antibody frameworks
- frameworks
- novel
- novelantibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13003264 | 2013-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201811017QA true SG10201811017QA (en) | 2019-01-30 |
Family
ID=48699516
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201811017QA SG10201811017QA (en) | 2013-06-26 | 2014-06-26 | Novel antibody frameworks |
| SG11201509899PA SG11201509899PA (en) | 2013-06-26 | 2014-06-26 | Novel antibody frameworks |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509899PA SG11201509899PA (en) | 2013-06-26 | 2014-06-26 | Novel antibody frameworks |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10174102B2 (zh) |
| EP (1) | EP3013864A1 (zh) |
| JP (4) | JP6708544B2 (zh) |
| KR (4) | KR20210097829A (zh) |
| CN (2) | CN105579472B (zh) |
| AU (2) | AU2014301629B2 (zh) |
| CA (1) | CA2914829A1 (zh) |
| HK (1) | HK1218549A1 (zh) |
| IL (2) | IL243311B (zh) |
| NZ (1) | NZ714320A (zh) |
| SG (2) | SG10201811017QA (zh) |
| WO (1) | WO2014206561A1 (zh) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6708544B2 (ja) | 2013-06-26 | 2020-06-10 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | 新規抗体フレームワーク |
| CN107922486B (zh) | 2015-06-15 | 2022-05-31 | 努玛治疗有限公司 | 异源二聚体多特异性抗体形式 |
| BR112018067698A2 (pt) | 2016-02-25 | 2019-01-08 | Cell Medica Switzerland Ag | células modificadas para imunoterapia |
| HUE052869T2 (hu) | 2016-03-17 | 2021-05-28 | Tillotts Pharma Ag | TNF-ellenes alfa-antitestek és ezek funkcionális fragmentjei |
| WO2017158079A1 (en) | 2016-03-17 | 2017-09-21 | Numab Innovation Ag | Anti-tnfalpha-antibodies and functional fragments thereof |
| US10759852B2 (en) | 2016-03-17 | 2020-09-01 | Numab Innovation Ag | Anti-TNF-alpha-antibodies and functional fragments thereof |
| ES2836349T3 (es) | 2016-03-17 | 2021-06-24 | Tillotts Pharma Ag | Anticuerpos anti-TNF-alfa y fragmentos funcionales de los mismos |
| CA3016870A1 (en) | 2016-03-17 | 2017-09-21 | Numab Innovation Ag | Anti-tnf.alpha.-antibodies and functional fragments thereof |
| GB201621591D0 (en) * | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Antibody molecules and method |
| WO2018224441A1 (en) | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| WO2018224439A1 (en) | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-hsa antibodies |
| US11365240B2 (en) | 2017-06-05 | 2022-06-21 | Numab Therapeutics AG | Anti-HSA antibodies |
| JP2020522267A (ja) | 2017-06-05 | 2020-07-30 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | 少なくともｃｄ３及びｈｓａを標的とするヘテロ二量体多重特異性抗体フォーマット |
| SG11201912864SA (en) * | 2017-06-25 | 2020-01-30 | Systimmune Inc | Multi-specific antibodies and methods of making and using thereof |
| WO2019005640A2 (en) * | 2017-06-25 | 2019-01-03 | Systimmune, Inc. | MULTISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING SAME |
| EP3459968A1 (en) | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Novel stable antibody variable domain framework combinations |
| WO2020157305A1 (en) | 2019-01-31 | 2020-08-06 | Numab Therapeutics AG | Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof |
| EP3689907A1 (en) | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
| WO2022147338A1 (en) * | 2020-12-30 | 2022-07-07 | Ascendo Biotechnology, Inc. | Monoclonal antibody against human mac-1 and uses thereof |
| CA3208905A1 (en) | 2021-02-12 | 2022-08-18 | Boehringer Ingelheim International Gmbh | Complement c3 antigen binding proteins |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| JP2007520991A (ja) | 2003-08-07 | 2007-08-02 | エピトミクス インコーポレーティッド | ウサギ単クローン抗体をヒト型化する方法 |
| WO2008004834A1 (en) | 2006-07-06 | 2008-01-10 | Isu Abxis Co., Ltd | Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor |
| TWI609965B (zh) | 2007-05-21 | 2018-01-01 | 艾爾德生物控股有限責任公司 | 新穎兔抗體人化方法以及經人化之兔抗體 |
| CN103435696B (zh) | 2007-06-25 | 2016-10-12 | 艾斯巴技术-诺华有限责任公司 | 修饰抗体的方法和具有改善的功能性质的修饰抗体 |
| HUE032894T2 (hu) * | 2008-06-25 | 2017-11-28 | Esbatech Alcon Biomed Res Unit | VEGF-gátló, stabilis és oldható antitestek |
| BRPI0914319B8 (pt) * | 2008-06-25 | 2021-05-25 | Esbatech Alcon Biomed Res Unit | imunoligante que se liga especificamente ao tnf alfa humano e composição |
| PL2307458T3 (pl) * | 2008-06-25 | 2018-08-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała |
| US8193235B2 (en) | 2009-06-12 | 2012-06-05 | University Of Kansas | Compositions and methods for establishing and maintaining stem cells in an undifferentiated state |
| JP6708544B2 (ja) | 2013-06-26 | 2020-06-10 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | 新規抗体フレームワーク |
| EP3459968A1 (en) | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Novel stable antibody variable domain framework combinations |
-
2014
- 2014-06-26 JP JP2016522319A patent/JP6708544B2/ja active Active
- 2014-06-26 EP EP14737144.7A patent/EP3013864A1/en active Pending
- 2014-06-26 NZ NZ714320A patent/NZ714320A/en unknown
- 2014-06-26 KR KR1020217024096A patent/KR20210097829A/ko not_active Application Discontinuation
- 2014-06-26 KR KR1020227006072A patent/KR20220029763A/ko not_active IP Right Cessation
- 2014-06-26 US US14/900,550 patent/US10174102B2/en active Active
- 2014-06-26 WO PCT/EP2014/001730 patent/WO2014206561A1/en active Application Filing
- 2014-06-26 SG SG10201811017QA patent/SG10201811017QA/en unknown
- 2014-06-26 AU AU2014301629A patent/AU2014301629B2/en active Active
- 2014-06-26 IL IL243311A patent/IL243311B/en unknown
- 2014-06-26 KR KR1020167001339A patent/KR102286053B1/ko active IP Right Grant
- 2014-06-26 CA CA2914829A patent/CA2914829A1/en active Pending
- 2014-06-26 CN CN201480036689.1A patent/CN105579472B/zh active Active
- 2014-06-26 CN CN202111136784.7A patent/CN113943366A/zh active Pending
- 2014-06-26 IL IL293477A patent/IL293477A/en unknown
- 2014-06-26 SG SG11201509899PA patent/SG11201509899PA/en unknown
- 2014-06-26 KR KR1020237043185A patent/KR20240000622A/ko active Search and Examination
-
2016
- 2016-05-27 HK HK16106054.2A patent/HK1218549A1/zh unknown
-
2018
- 2018-10-10 US US16/156,036 patent/US11427628B2/en active Active
-
2019
- 2019-06-17 JP JP2019111990A patent/JP2019201643A/ja not_active Withdrawn
-
2020
- 2020-04-27 AU AU2020202770A patent/AU2020202770B2/en active Active
-
2021
- 2021-10-14 JP JP2021169020A patent/JP2022028659A/ja active Pending
-
2022
- 2022-08-29 US US17/822,959 patent/US20230212265A1/en active Pending
-
2023
- 2023-11-27 JP JP2023199881A patent/JP2024026176A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024026176A (ja) | 2024-02-28 |
| US10174102B2 (en) | 2019-01-08 |
| EP3013864A1 (en) | 2016-05-04 |
| CN113943366A (zh) | 2022-01-18 |
| IL243311B (en) | 2022-07-01 |
| CN105579472B (zh) | 2021-10-22 |
| KR20160024923A (ko) | 2016-03-07 |
| KR102286053B1 (ko) | 2021-08-04 |
| JP2016523537A (ja) | 2016-08-12 |
| JP6708544B2 (ja) | 2020-06-10 |
| SG11201509899PA (en) | 2016-01-28 |
| US11427628B2 (en) | 2022-08-30 |
| IL293477A (en) | 2022-08-01 |
| US20230212265A1 (en) | 2023-07-06 |
| JP2022028659A (ja) | 2022-02-16 |
| KR20210097829A (ko) | 2021-08-09 |
| KR20220029763A (ko) | 2022-03-08 |
| AU2020202770A1 (en) | 2020-05-14 |
| AU2014301629B2 (en) | 2020-02-06 |
| JP2019201643A (ja) | 2019-11-28 |
| CN105579472A (zh) | 2016-05-11 |
| HK1218549A1 (zh) | 2017-02-24 |
| US20160130326A1 (en) | 2016-05-12 |
| KR20240000622A (ko) | 2024-01-02 |
| NZ714320A (en) | 2022-02-25 |
| WO2014206561A8 (en) | 2016-02-18 |
| CA2914829A1 (en) | 2014-12-31 |
| IL243311A0 (en) | 2016-03-31 |
| AU2020202770B2 (en) | 2023-01-05 |
| WO2014206561A1 (en) | 2014-12-31 |
| US20190119359A1 (en) | 2019-04-25 |
| AU2014301629A1 (en) | 2015-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201811017QA (en) | Novel antibody frameworks | |
| PH12016501763A1 (en) | Multispecific antibodies | |
| PH12016501700A1 (en) | Combination therapies with anti-cd38 antibodies | |
| EA201591750A1 (ru) | Антитела против b7-h4 и иммуноконъюгаты | |
| AU357215S (en) | Positioning element for construction toy | |
| IN2013DE00266A (zh) | ||
| IN2014DE01038A (zh) | ||
| TWD163873S (zh) | 手錶 | |
| FR3007636B1 (fr) | Trocart perforant. | |
| AU350360S (en) | Filtration components | |
| PL3077434T3 (pl) | Układ reakcji dla pianki poliuretanowej 1-K o niskiej zawartości monomeru | |
| MX366815B (es) | Polioles, su preparación y su uso. | |
| AU350093S (en) | Compact | |
| TN2013000364A1 (fr) | تصميم جديد لطائرة مدنية ذات مقعد واحد و انظمة سلامة متطورة | |
| TWD162356S (zh) | 眼鏡 | |
| AU353233S (en) | Novelty Pen | |
| TWD160691S (zh) | 眼鏡 | |
| UA80877U (en) | 2-hydroxyethyl-1,3,4-trimethylcyclohex-3-ene-1-carboxylate | |
| UA89695U (en) | Lisoverm, complex antiparasitic composition | |
| IN2013CH00453A (zh) | ||
| TWD162135S (zh) | 眼鏡框 | |
| TWD160310S (zh) | 風鏡 | |
| TWD160688S (zh) | 眼鏡框 | |
| TWD160311S (zh) | 眼鏡框 | |
| AU350357S (en) | Filtration components |